OPUS GENETICS INC (IRD) competitors & alternatives
Health Care · NASDAQ
OPUS GENETICS INC (IRD)'s top competitors and alternatives — its most similar public companies — include 4D MOLECULAR THERAPEUTICS INC (FDMT), EDITAS MEDICINE INC (EDIT), OCUGEN INC (OCGN), X4 PHARMACEUTICALS INC (XFOR), REGENXBIO INC (RGNX), ABEONA THERAPEUTICS INC (ABEO), TAYSHA GENE THERAPIES INC (TSHA), ROCKET PHARMACEUTICALS INC (RCKT), MEIRAGTX HOLDINGS PLC (MGTX), Ultragenyx (RARE), NEUROGENE INC (NGNE) and VOYAGER THERAPEUTICS INC (VYGR). These are OPUS GENETICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IRD competitors & alternatives
-
4D MOLECULAR THERAPEUTICS INCFDMTHealth Care
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary…
$10.96 (as of 2026-07-22) · market cap $573M
-
EDITAS MEDICINE INCEDITHealth Care
A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL…
$2.78 (as of 2026-07-22) · market cap $421M
-
OCUGEN INCOCGNHealth Care
A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and…
$1.29 (as of 2026-07-22) · market cap $440M
-
X4 PHARMACEUTICALS INCXFORHealth Care
A commercial-stage biopharmaceutical company focused on developing and marketing targeted therapies for rare immune system disorders, headlined by its…
$3.69 (as of 2026-07-22) · market cap $361M
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.20 (as of 2026-07-22) · market cap $529M
-
ABEONA THERAPEUTICS INCABEOHealth Care
Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for…
$6.42 (as of 2026-07-22) · market cap $374M
-
TAYSHA GENE THERAPIES INCTSHAHealth Care
Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous…
$5.66 (as of 2026-07-22) · market cap $1.8B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
MEIRAGTX HOLDINGS PLCMGTXHealth Care
A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and…
$12.16 (as of 2026-07-22) · market cap $1.1B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
NEUROGENE INCNGNEHealth Care
Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating…
$36.11 (as of 2026-07-22) · market cap $721M
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
Not quite? Describe exactly what you want →
Peers are OPUS GENETICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: OPUS GENETICS INC (IRD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.